CAC
TVRD

Cowen and Company’s Tvardi Therapeutics TVRD Stock Holding History

Cowen and Company’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-719
Closed -$562K – 724
2021
Q1 		$562K Buy
+719
New +$492K 0.04% 177

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Cowen and Company's TVRD Position: Q2 2021 in Review

Cowen and Company sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 719 shares — an estimated $562K sold.

Cowen and Company first reported a position in TVRD in Q1 2021 and held it in 1 quarter. The position peaked at $562K in Q1 2021. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • Cowen and Company reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Cowen and Company sold 719 Tvardi Therapeutics shares in Q2 2021, an estimated $562K.
  • Cowen and Company first reported a position in Tvardi Therapeutics in Q1 2021 and held it in 1 quarter.
  • Cowen and Company's Tvardi Therapeutics position peaked at $562K in Q1 2021.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on Cowen and Company's 13F filing for Q2 2021, filed 13 Aug 2021.